Book ChapterDOI
Response-Related Predictors of Survival and of Treatment-Free Remission in CML
Susan Branford,Naranie Shanmuganathan,Timothy P. Hughes +2 more
- pp 245-264
Reads0
Chats0
TLDR
Recently, the importance of determining the dynamics of response, not just the BCR-ABL1 level at one specified time point, has been recognized, particularly when determining the probability of achieving sustained TFR in eligible patients.Citations
More filters
Establishment of the 1st world health organization international genetic referrence panel for quantitation of BCR-ABL mRNA
E. White,P. Matejtschuk,P. Rigsby,J. Gabert,Yirong Wang,S. Branford,N. Muller,N. Beaufils,Emmanuel Beillard,Dolors Colomer,Dana Dvořáková,H. Ehrencrona,Hyun-Gyung Goh,El H. Housni,D. Jones,Veli Kairisto,S. Kamel-Reid,Dw. Kim,S. Langabeer,E. Ma,RD Press,G. Romeo,L. Wang,Katerina Zoi,Timothy P. Hughes,G. Saglio,A. Hochhaus,J. Goldman,P. Metcalfe,Ncp. Cross +29 more
TL;DR: The development of accredited reference reagents that are directly linked to the BCR-ABL international scale is considered a significant milestone in the standardization of this clinically important test, but because they are a limited resource it is suggested that their availability is restricted to manufacturers of secondary reference materials.
Journal Article
t(9;22)(q34;q11) with the BCR-ABL mBCR fusion gene transcript - in: "Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program"
J. L. E. Aerts,David Grimwade,P. Vandekerckhove,A. Navarrete,R. Flora,J. Krauter,G. Heil,Susanne Viehmann,Claude Preudhomme,N. Grardel Duflos,Fabrizio Pane,Mariano Intrieri,Francesco Salvatore,Nicholas C.P. Cross,Jaspal Kaeda,Maria Malec,A. Porwitt,Y. Toyron,M J Mozziconacci,M. Lafage Pochitaloff +19 more
TL;DR: In this paper, a TaqMan-based real-time quantitative PCR (RQ-PCR) analysis of the main leukemia-associated fusion gene (FG) transcripts within the Europe Against Cancer (EAC) program is presented.
Meeting the Needs of CML Patients in Resource-Poor Countries: a Roundtable Discussion
TL;DR: In this article, the authors discuss the challenges of providing optimal treatment to patients with chronic myeloid leukemia in resource-poor countries, including low and middle-income countries, by using a more objective country label.
References
More filters
Journal ArticleDOI
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Journal ArticleDOI
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
Jean Gabert,Emmanuel Beillard,V H J van der Velden,Wanli Bi,David Grimwade,Niels Pallisgaard,Gisela Barbany,Giovanni Cazzaniga,Jean Michel Cayuela,Hélène Cavé,Fabrizio Pane,J. L. E. Aerts,D De Micheli,X Thirion,V Pradel,Marcos González,Susanne Viehmann,Maria Malec,Giuseppe Saglio,J. J. M. Van Dongen +19 more
TL;DR: The development of standardized protocols for RQ-PCR analysis of FG transcripts provides a milestone for molecular determination of MRD levels and is likely to prove invaluable to the management of patients entered into multicenter therapeutic trials.
Journal ArticleDOI
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon,Delphine Rea,Joelle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Etienne,Josy Reiffers,Philippe Rousselot +12 more
TL;DR: Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors.
Journal ArticleDOI
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
Timothy P. Hughes,Jaspal Kaeda,Susan Branford,Zbigniew Rudzki,Andreas Hochhaus,Martee L. Hensley,Insa Gathmann,Ann E. Bolton,Iris C. van Hoomissen,John M. Goldman,Jerald P. Radich +10 more
TL;DR: The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine.
Journal ArticleDOI
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani,Jorge E. Cortes,Fabrizio Pane,Dietger Niederwieser,Giuseppe Saglio,Jane F. Apperley,Francisco Cervantes,Michael W. Deininger,Alois Gratwohl,François Guilhot,Andreas Hochhaus,Mary M. Horowitz,Timothy P. Hughes,Hagop M. Kantarjian,Richard A. Larson,Jerald P. Radich,Bengt Simonsson,Richard T. Silver,John M. Goldman,Rüdiger Hehlmann +19 more
TL;DR: Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.